CanSinoBIO Reports Outstanding H1 2024 Performance
HONG KONG, Aug 29, 2024 – (ACN Newswire via SeaPRwire.com) – CanSino Biologics Inc. (CanSinoBIO) today disclosed its performance report for the first half of 2024, with revenue reaching 303 million yuan, while losses were substantially reduced. The meningococcal conjugate vaccines demonstrated robust growth, particularly the Group ACYW135 Meningococcal Conjugate Vaccine (CRM197), known as MCV4... » read more